Literature DB >> 33119882

B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine?

Dário Ligeiro1, Martin Rao2, Andreia Maia3, Mireia Castillo3, Antonio Beltran3, Markus Maeurer4,5.   

Abstract

We review state-of-the-art in translational and clinical studies focusing on the tumor microenvironment (TME) with a focus on tumor-infiltrating B cells (TIBs). The TME is a dynamic matrix of mutations, immune-regulatory networks, and distinct cell-to-cell interactions which collectively impact on disease progress. We discuss relevant findings concerning B cells in pancreatic cancer, the concepts of "bystander" B cells, the role of antigen-specific B cells contributing to augmenting anticancer-directed immune responses, the role of B cells as prognostic markers for response to checkpoint inhibitors (ICBs), and the potential use in adoptive cell tumor-infiltrating lymphocyte (TIL) products.

Entities:  

Keywords:  Adjuvant therapy; Antibody; B cells; Breg; CDR3; Chemotherapy; Complement; Cytokines; ICB; Immune checkpoint inhibition; Immune responses; Immunosuppression; Inflammation; Pancreatic cancer; Prognostic markers; RNA profiling; TIB; TIL; Therapy

Mesh:

Year:  2020        PMID: 33119882     DOI: 10.1007/978-3-030-49270-0_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  1 in total

1.  Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program.

Authors:  Hassana El Haddaoui; Rianne Brood; Diba Latifi; Astrid A Oostvogels; Yarne Klaver; Miranda Moskie; Dana A Mustafa; Reno Debets; Casper H J van Eijck
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.